IDAC Theranostics is a pioneering biopharmaceutical company dedicated to providing high-quality medications and reagents that cater to specific needs. With a strong focus on innovation in drug development, particularly in inflammatory diseases and cancer, IDAC Theranostics aims to address unmet medical needs by utilizing the latest scientific knowledge and research methodologies. The company actively promotes collaborative research with academia and strives to establish partnerships that allow for global expansion.

IDAC Theranostics takes its name from Inflammatory Disease And Cancer (IDAC), symbolizing its commitment to tackling these conditions. The combination of theranostics represents the belief that the convergence of therapy and diagnosis leads to meaningful contributions to patients. Established in 2012 as a university spin-off venture, IDAC Theranostics has steadily grown and forged key partnerships, securing exclusive rights for the development and implementation of humanized anti-human CD4 antibodies.

Based in Tokyo, the company continues to thrive and make significant contributions to healthcare